Latest Breaking News On - Syntonix pharmaceuticals - Page 1 : comparemela.com
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO
April 07, 2021 08:00 ET | Source: Arch Oncology Arch Oncology Brisbane, California, UNITED STATES
BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member. Dr. Blumberg has over thirty years of biotechnology industry experience leading companies as an executive, founder, analyst, and board member.
“On behalf of the Board, I welcome Laur to Arch Oncology as he brings extensive industry experience to lead the Company’s plans for AO-176, a novel anti-CD47 therapy for patients with cancer,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology.
Brisbane
Queensland
Australia
John-mckearn
Laurence-blumberg
Arch-oncology-inc
Brandeis-university
Temple-university-school-of-medicine
Columbia-university-school-of-business
Geisinger-medical-center
Kadmon-corporation
Syntonix-pharmaceuticals
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO
News Provided By
Share This Article
/EIN News/ BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member. Dr. Blumberg has over thirty years of biotechnology industry experience leading companies as an executive, founder, analyst, and board member.
“On behalf of the Board, I welcome Laur to Arch Oncology as he brings extensive industry experience to lead the Company’s plans for AO-176, a novel anti-CD47 therapy for patients with cancer,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology. “AO-176 has a differentiated and potentially best-in-class profile among anti-CD47 biologic therap
Brisbane
Queensland
Australia
John-mckearn
Samy-figueroa
Laurence-blumberg
Arch-oncology-inc
Brandeis-university
Temple-university-school-of-medicine
Columbia-university-school-of-business
Geisinger-medical-center
Healthcare-pharmaceuticals-industry